Skip to main content
TipRanks
Go Ultimate75% OFF

BICO Group AB Class B (CLLKF) Q3 2026 Earnings Report

34 Followers

CLLKF Q3 2026 EPS Results

Actual EPS
-$0.31
Consensus EPS
$0.12
Beat/Miss
Missed by -$0.43
One Year Ago EPS
-$1.56

CLLKF Q3 2026 Revenue Results

Actual Revenue
$46.17M
Expected Revenue
$51.52M
Beat/Miss
Missed by -$5.35M
YoY Revenue Growth
+20.24%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/11/2026
Time
Before Open
Conference Call
Wednesday, November 11, 2026
CLLKF Upcoming Earnings

BICO Group AB Class B's next earnings date is estimated for February 17, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

CLLKF Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 11, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Neutral

The call presented a strong Q3 with 19% organic sales growth, 14% growth in own benchtop instruments, a 27% adjusted EBITDA margin, restructuring progress, and a clear new precision-biology strategy. However, reported profitability benefited materially from a one-time SCIENION agreement, operating cash flow was negative, working capital was elevated, academic demand remained weak, and Biosero required a substantial SEK 296 million impairment and strategic reassessment. Overall, the positive operating momentum and strategic clarity were offset by significant execution, cash conversion, and Biosero-related challenges.

Company Guidance

BICO reconfirmed its long-term financial targets of double-digit organic growth in constant currencies, an EBITDA margin less capitalized development costs above 10%, and net debt-to-EBITDA below 3x, with new long-term financial targets to be defined once the current targets have been achieved. The restructuring program is expected to generate around SEK 30 million in annual savings, with the full effect expected later in Q4. Management said it does not give forecasts, expects the margin to be around the same level, and will ramp up for key product launches in 2027.

  • Strong Q3 Revenue GrowthNet sales reached SEK 465 million, increasing 20% quarter-over-quarter and 19% organically.
  • Underlying Benchtop and Consumables GrowthExcluding the large-scale integrated automation project business, instrument sales grew 14% and consumables sales grew 5%. BICO's own benchtop instruments continued to perform well, with sales up 14%.
  • High Adjusted EBITDA and Improved Cost DisciplineAdjusted EBITDA was SEK 124 million, corresponding to a 27% adjusted EBITDA margin. Sales and administration expenses, personnel costs, and external services were lower than a year ago, reflecting restructuring actions and continued cost discipline.
  • SCIENION Supply and License AgreementSCIENION signed extended supply and license agreements with a diagnostic customer, contributing SEK 135 million in Q3 revenue, including SEK 83 million of license revenue recognized at a point in time. The agreements have an estimated combined contractual value of approximately EUR 50 million over a 10-year term.
  • Improved Gross Profit Excluding Agreement ImpactGross profit improved mainly due to the SCIENION agreement, but also remained stronger than the same quarter last year excluding that effect, supported by favorable product mix and outsourced production.
  • BICO 2030 Precision Biology StrategyBICO launched BICO 2030, focusing resources on precision biology, cell solutions, and 3D cell models where management believes its competitive advantage is strongest. The strategy is intended to support sustainable growth, improved profitability, and stronger cash generation.
  • Focus on Attractive Growth MarketsBICO identified three growing markets worth around $10 billion in total: 3D biology and biomaterials at $2.7 billion, growing at low double digits; cell imaging, isolation, and cell line development at $3.4 billion, growing at high single digits; and wet-lab automation at $4.1 billion, growing at mid- to high single digits. BICO's current serviceable market is approximately $1.5 billion, growing an estimated 4% to 7% annually.
  • Shift Toward Higher-Quality Revenue StreamsThe strategy calls for accelerating organic growth in instruments, increasing the share of consumables, services, and software, and reducing exposure to large customized projects. BICO stated that it remains committed to lab automation but is moving away from large, highly customized integration projects built around third-party instruments and hardware.
  • AI-Enabled Product and R&D PrioritiesBICO plans to align R&D more closely with customer demand, use AI in product development, make instruments ready for software agents and robots, increasingly incorporate AI into products, and pursue selective bolt-on acquisitions. Management expects this to support higher returns on R&D, faster development, and software revenue from the installed base.
  • Restructuring Savings ProgressThe integration of Cellenion into SCIENION was completed after quarter-end as the main part of the restructuring program initiated in Q1. The program is expected to generate around SEK 30 million in annual savings, with some effects already visible in Q3 and the full effect expected later in Q4.
  • Strong Balance Sheet PositionBICO ended the quarter with cash equivalents of SEK 555 million and a net cash position of SEK 124 million. The Biosero impairment was described as a noncash charge with no effect on liquidity or covenants.
  • Market Improvement in Pharma, Biotech, and DiagnosticsManagement reported that pharma and biotech demand had strengthened over the last few months and that diagnostics had performed adequately. Customer discussions and industry events indicated that conditions were normalizing after earlier tariff-related uncertainty and geopolitical tensions.
  • Strengthened Executive ManagementBICO added a Chief Technology Officer and new Managing Directors for Lab Instruments and CELLINK, bringing business leadership closer to group decision-making and strengthening links between customers, commercial priorities, and technology development.
  • Long-Term Financial Targets ReconfirmedThe Board reconfirmed the existing long-term targets of double-digit organic growth in constant currencies, an EBITDA margin less capitalized development costs above 10%, and net debt-to-EBITDA below 3x.
  • Positive Instrument Demand Across Key SegmentsManagement reported strong Q3 instrument momentum, with some recovery in academia and good progress in diagnostics, pharma, and biotech. Management also stated that its instruments are well positioned for the current AI-driven increase in demand for wet-lab services and capabilities.

CLLKF Earnings History

CLLKF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 17, 20272026 (Q4)-0.00--0.08――
Nov 11, 20262026 (Q3)0.12-0.31-1.5680.27% (+1.25)
Aug 19, 20262026 (Q2)-0.07-0.05-0.2580.31% (+0.20)
Apr 29, 20262026 (Q1)-0.10-0.15-0.3352.74% (+0.17)
Feb 18, 20262025 (Q4)-0.05-0.080.36-122.47% (-0.44)
Nov 04, 20252025 (Q3)-0.10-1.56-0.36-333.38% (-1.20)
Aug 19, 20252025 (Q2)-0.12-0.25-0.11-137.38% (-0.15)
Apr 29, 20252025 (Q1)-0.12-0.33-0.04-709.88% (-0.29)
Feb 19, 20252024 (Q4)-0.020.36-0.84142.97% (+1.21)
Nov 26, 20242024 (Q3)-0.04-0.36-0.1-269.90% (-0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed